Nasdaq
$1.88▼ 1.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $93.7MShares out 49.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.1After-hours26.09.02 05:308-KKey event#●●●#●●●#●●●
Polaryx Therapeutics, Inc.
Polaryx Therapeutics appointed Dr. Will Charlton as Chief Medical Officer, effective September 1, 2026. This appointment is intended to strengthen clinical leadership and execution capabilities ahead of the planned initiation of the SOTERIA Phase 2 trial for its lead candidate, PLX-200, in the fourth quarter of 2026.…more
$1.88-1.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 7.28After-hours26.07.29 06:04ARSOther
Polaryx Therapeutics, Inc.
Polaryx Therapeutics가 2025년 12월 31일 회계연도 기준 연례 보고서(ARS)를 제출했습니다. 해당 공시는 회사의 재무 상태와 사업 운영 현황을 담고 있으며, 투자자는 이를 통해 기업의 연간 실적과 향후 사업 방향을 확인할 수 있습니다.…more
$1.88-1.05%vs prev closeView filingShare - 7.28After-hours26.07.29 06:01DEFA14AOther
Polaryx Therapeutics, Inc.
Polaryx Therapeutics는 2026년 9월 10일 오전 9시(동부 표준시)에 연례 주주총회를 개최합니다. 이번 총회에서는 Alex Yang과 Mitchel Berger를 Class I 이사로 선출하고, 2026 회계연도 외부감사인으로 Grant Thornton LLP를 선임하는 안건을 다룹니다.…more
$1.88-1.05%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.1Pre-market26.09.01 21:30#●●●#●●●
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer…more
Polaryx Therapeutics has appointed Dr. Will Charlton, an expert in rare disease drug development, as its new Chief Medical Officer. This leadership addition aims to strengthen clinical execution ahead of the planned initiation of the SOTERIA Phase 2 trial in Q4 2026.…more
$1.88-1.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.25Pre-market26.08.25 21:32
●●●●●●●● ●●●●● ●●●●●●
Polaryx Therapeutics announced that it remains on track to initiate the Phase 2 SOTERIA basket trial for PLX-200 in late 2026. The trial focuses on treating four pediatric lysosomal storage disorders.…more
$1.88-1.05%vs prev closeShareBenzinga - 8.25Pre-market26.08.25 21:30
●●●●●●●● ●●●●● ●●●●●●
Polaryx Therapeutics plans to initiate its Phase 2 basket trial for the rare pediatric disease candidate PLX-200 in the fourth quarter of 2026. The company has secured FDA Fast Track designation and necessary funding to proceed with the clinical development program.…more
$1.88-1.05%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report